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INTRODUCTION
According to recent studies, pathological complete response
(pCR) after neoadjuvant chemotherapy (NAC) in node posi-
tive breast cancer is observed in up to 40–75% of cases
(Dominici et al., 2010; Boughey et al., 2014; Diego et al.,
2016; Koolen et al., 2017). This means that the preoperative
systemic therapy has completely eliminated all regional
cancer involvement and total removal of all axillary lymph
nodes is not indicated. However, until recently, axillary
lymph node dissection (ALND) was performed in all node
positive cases irrespective of response to NAC. According
to a retrospective study performed in Pauls Stradiòð Clinical
University Hospital, total removal of unaffected axillary
lymph nodes after NAC was performed in 31.6% of cases
before 2016 (Puzâka and Irmejs, 2016). Restaging of axilla
after NAC for node positive breast cancer is recommended
according to the latest NCCN guidelines for breast cancer.
However, the ways to achieve optimal axillary management
after NAC are still not known (NCCN Breast Cancer Clini-
cal Guidelines, Version 1.2018) (Vugts et al., 2016). Sev-
eral preoperative and intraoperative axillary reevaluation
approaches have been studied recently, including physical
examination, imaging (e.g. ultrasound, PET-CT) and biopsy
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The aim of the study was to evaluate the role of ultrasound guided fine needle aspiration cytology
(FNAC) in the restaging of node positive breast cancer after neoadjuvant chemotherapy (NAC).
From January 2016 – October 2018, 90 node positive stage IIA-IIIC breast cancer cases under-
going NAC were included in the study. The largest, most superficial and the most caudal axillary
node metastasis confirmed by fine needle aspiration cytology (FNAC) was marked with clip. After
NAC, restaging of axilla was performed with ultrasound and FNAC of the marked and/or the most
suspicious axillary node. Of the 90 cases, 58 with available ultrasound guided percutaneous nee-
dle biopsy data were further evaluated. Axilla conserving surgery was performed in 37 of 58
cases and axillary lymph node dissection (ALND) in 21 of 58 cases. False Positive Rate (FPR) of
FNAC after NAC was 12%, False Negative Rate (FNR) — 58%, sensitivity — 54%, specificity —
82%, accuracy 62%. FNAC after NAC had low FPR and was found to be useful in predicting re-
sidual axillary disease and to streamline surgical decision making regarding ALND. However,
FNR was unacceptably high and FNAC alone was not able to predict ypCR and omission of fur-
ther axillary surgery.
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techniques (Boughey et al., 2015; Caudle et al., 2016).
Studies on PET/CT imaging for axillary staging after NAC
are controversial (Koolen et al., 2014). The combined
clipped and sentinel node biopsy approach has a very low
false negative rate 1.4%, but a disadvantage is the necessity
of intraoperative frozen section and/or potential for repeated
axillary surgery in cN2 and cN3 cases (Caudle et al., 2016).
FNAC or core needle biopsy has been widely used to evalu-
ate axillary nodal status in cases of breast cancer, but to the
best of our knowledge there have been no reports on axil-
lary lymphnode FNAC accuracy after NAC. The aim of the
study was to evaluate the role of FNAC in the restaging of
node positive breast cancer after NAC.
MATERIALS AND METHODS
The prospective cohort study was carried out at the state ter-
tiary healthcare institution. The study was approved by the
decision of Pauls Stradiòð Clinical University Hospital
Medical Committee for Research Ethics. Patients signed a
written informed consent.
From January 2016 to October 2018, 90 node positive stage
IIA-IIIC breast cancer cases undergoing NAC were in-
cluded in the study. Of these, 25 (28%) of cases were HER2
positive, 16 (18%) triple negative (TN) and 49 (54%) Lumi-
nal. Cases were considered as TN if HER2 was negative
and estrogen/progesteron was < 10%. Of the 90 cases, 84
(93%) had ductal, 5 (6%) cases — lobular and 1 (1%) me-
dullary pathologies. Thirteen (14%) cases were BRCA1
positive.
The largest, most superficial and the most caudal axillary
node metastasis confirmed by fine needle aspiration cytol-
ogy (FNAC) was marked with a V-markTM Breast Biopsy
Site Marker with Titanium Anchor (Argon Medical De-
vices, Inc), which was not visible in ultrasound in a consid-
erable proportion of cases. Anchor localisation in the axil-
lary lymphnode was confirmed by CT scan when necessary.
The cN stage was diagnosed on the basis of pretreatment
imaging (ultrasound and CT) data, the cN1 stage was con-
sidered if 1-3 involved axillary nodes were identified, the
cN2 stage when more than three metastatic lymphnodes
were visualised in axilla, and the cN3 stage was diagnosed
if infra/supraclavicular lymphnode metastasis or more than
ten affected axillary nodes were detected. cN1, cN2 and
cN3 stages were observed in 56 (62%), 15 (17%) and 19
(21%) cases, respectively.
After NAC, restaging of axilla was performed with ultra-
sound and FNAC of the marked and/or the most suspicious
axillary node. During the last months of the study, lymph
node biopsy was performed with alternate core needle bi-
opsy method if technically possible. A modified algorithm
of Netherlands cancer institute/Antoni van Levenhoek hos-
pital (NCI/AVL) was followed to decide on axilla conserv-
ing surgery (ACS) versus ALND, as described by Koolen et
al. (2017) ( Fig. 1). Modifications in our study included no
use of PET-CT for clinical axillary staging and the clipped
node was removed together with sentinel nodes during ACS
to reduce false negative results of lymphnode pathology as
much as possible.
In order to assess the diagnostic value of ultrasound guided
FNAC, the false negative and false positive rate as well as
sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV) and accuracy were calcu-
lated. Statistical analyses were performed using Medcalc,
easy-to-use software and MS Excel 2010.
RESULTS
Of the 90 node positive stage IIA-IIIC breast cancer cases,
32 (36%) pCR cases in axilla were observed, among which
12 (38%) were HER2 positive, 11 (34%) Luminal and 9
(28%) were TN. There were considerably less Luminal can-
cers in the pCR group in comparison to full study group and
this difference almost reached statistical significance —
34% vs 54% (p = 0.0529). Downstaging and upstaging of
axillary nodal status after NAC took place in 56 (62%) and
5 (6%) cases, respectively. Axillary lymphnode percutane-
ous needle biopsy (FNAC or CNB) data after NAC were
available in 55 of 90 (61%) cases: 49 (89%) — FNAC and
6 (11%) — CNB. In another three (3%) cases, FNAC after
NAC was proposed, but not performed because all axillary
lymphnodes had a normal structure in ultrasound and none
were greater than 5 mm, which would have made FNA
technically challenging and questionable. Those cases also
were included in further evaluation and were considered as
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Fig. 1. Proposed axillary treatment after combining
PET-CT before neoadjuvant systemic therapy
(NST) and marking the axilla with radioactive io-
dine seeds (MARI procedure) after NST.
biopsy negative cases after NAC. Altogether 58 cases were
included for evaluation, of which 31 (54%) were Luminal,
17 (29%) — HER2 positive and 10 (17%) showed TN (Ta-
ble 1). Further, in 25 (43%) cases malignant cells persisted
in axillary lymphnodes in FNAC, and in 33 (57%) cases no
malignancy was detected, including one uninformative
specimen.
In the 58 cases, 37 axilla conserving surgeries (ACS) and 21
ALND were performed. The number of examined nodes in
the ACS group was 1–9, average 5 and in the ALND group
— 8 to 30, average 16. The difference between the number
of retrieved nodes in ACS and ALND was statistically sig-
nificant (p < 0.0001).
In 22 of 25 (88%) cases with positive FNCA after NAC,
metastasis in axillary lymphnodes was revealed in the pa-
thology examination of the surgery specimen. ypN1mic,
ypN1, ypN2 and ypN3 stages were detected in 1, 11, 7 and
3 cases, respectively. The false positive rate (FPR) of
FNAC after NAC was 3 of 25 (12%) cases. In the subgroup
of 33 cases with negative lymphnode FNAC after NAC,
surgery specimen examination revealed ypN0, ypN1mi,
ypN1, ypN2 and ypN3 stages in 14, 5, 11, 2 and 1 cases, re-
spectively. The false negative rate (FNR) of FNCA after
NAC was 19 of 33 (58%). Sensitivity, specificity, positive
and negative predictive value as well accuracy of the test
are shown in Table 2.
In further analysis of FNR and FPR subgroups, 13 of 22
(59%) cases had the Luminal subtype, 8/22 (36%) were
HER2 positive, and TN occurred in 1 (5%) case. The pro-
portion of TN cases was considerably less in FNR and FPR
subgroups — 10 of 58 (17.2%) vs 1 of 22 (4.5%), which
may suggest that in the TN breast cancer group, FNA could
have lower FNR and FPR and higher accuracy. However,
this difference was not statistically significant (p = 0.1442).
A larger sample size is required to confirm that FNR and
FPR rates after NAC are less in the TN molecular subtype.
Interestingly, FNR and FPR was 0% in the small subset of
BRCA1 positive cases (9 of 58, 16%), which suggests an-
other potential group in which percutaneous needle biopsy
techniques could be of important diagnostic value, but
again, a larger sample size is needed to confirm this.
DISCUSSION
Axillary pCR after NAC is a frequent event in the case of
breast cancer (Dominici et al., 2010; Boughey et al., 2014;
Diego et al., 2016; Koolen et al., 2017). Similarly, in our
cohort we report axillary pCR in 36% of NAC. Therefore, it
is very important to perform appropriate restaging in node
positive breast cancers after NAC to avoid unnecessary
ALND. One has to take in to account that pertuzumab is not
approved for NAC in our country and with dual HER2
blockade, the pCR rate is expected to be even higher.
ACS, including clipped node biopsy alone or in combina-
tion with SNB has very low FNR (Caudle et al., 2016;
Koolen et al., 2017) and is very good approach to restage
the axilla after NAC. However, in a large proportion of
node positive cases, especially in cN2 and cN3 stage, still
considerable residual nodal involvement remains, which re-
quires ALND. One solution is a use of a frozen section bi-
opsy, but this approach has several disadvantages: poten-
tially prolonged surgery time and rather high FNR — 33%
(Akay et al., 2018). This means that a considerable propor-
tion of cases potentially require repeated surgery to perform
ALND, which is not ideal management neither from the pa-
tient nor hospital perspective. Therefore, it is important in
particular cases to attempt axilla restaging preoperatively.
There are data on effectiveness of axillary ultrasound and
FNAC to evaluate nodal status prior to breast cancer treat-
ment, and use of the ultrasound method alone after NAC
has been evaluated (Pesek et al., 2017; Vijayaraghavan,
2017). However, to the best of our knowledge there are no
data available on accuracy of axillary lymphnode FNAC
and/or core needle biopsy (CNB) after NAC.
In our study, the false negative rate of FNCA after NAC
was 58% and sensitivity — 53.66%. The false positive rate
was 12% and specificity was 82.35%, with accuracy 62%.
In previous studies on the diagnostic value of axillary
FNAC prior to NAC, sensitivity, specificity and accuracy
have been estimated to lie between 41–80%, 96–100% and
70–89%, respectively, but methodological differences exist
(Ciatto et al., 2007; Cools-Lartigue and Meterissian, 2012;
Hieken et al., 2013; Gipponi et al., 2016; Vidya and Bick-
ley, 2017; Nakamura et al., 2018; Zhang et al., 2018). We
conclude that in our study sensitivity of FNAC was close to
the lowest range reported, but specificity and accuracy were
clearly lower. The accuracy of axillary FNAC after NAC
was somewhat lower than prior to NAC. Low sensitivity of
axillary FNAC together with high FNR in this setting pre-
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T a b l e 1
PATIENT GROUP CHARACTERISTICS BY CANCER SUBTYPE AND
PCR, WHO HAD AVAILABLE DATA ABOUT AXILLARY
LYMPHNODE PERCUTANEOUS NEEDLE BIOPSY (FNAC OR CNB)
AFTER NAC
Subtype n, % pCR, %
Luminal 31 (54%) 3 (10%)
HER2 positive 17 (29%) 6 (35%)
TN 10 (17%) 6 (60%)
T a b l e 2
FNAC SENSITIVITY, SPECIFICITY, POSITIVE AND NEGATIVE
PREDICTIVE VALUE AND ACCURACY AFTER NAC
Statistic Value 95% CI
Sensitivity 53.66% 37.42% to 69.34%
Specificity 82.35 % 56.57% to 96.20%
Positive predictive value 88.00% 71.64% to 95.51%
Negative predictive value 42.42 % 33.15% to 52.27%
Accuracy 62.07% 48.37% to 74.49%
cludes the omission of axillary surgery in spite of negative
cytology. However, low FPR and specificity of the test is
high enough to streamline surgical care with ALND for
node-positive patients with considerable residual cancer
burden expected. This approach has a potential to avoid fro-
zen section biopsy and repeated axillary surgery in particu-
lar cases.
There are also reports that sensitivity and specificity of axil-
lary ultrasound alone after NAC are 55% and 88 %, respec-
tively, which is very close to the results of our research
(You et al., 2015; Baumgartner et al., 2018; Le-Petross et
al., 2018). However, pathological confirmation of the ycN
stage is very important in surgical decision making, espe-
cially taking in to account that ultrasound method is highly
operator dependent.
Our results show a trend towards lower FPR and FNR in the
TN breast cancer subgroup, but a larger sample size is
needed to confirm this, and to determine the potential for
omission of axillary surgery in this subgroup on the basis of
percutaneous biopsy only.
One of the potential biases of the study was inclusion of a
small number of core needle biopsy cases. In a later stage of
our study, the responsible surgeon chose between FNAC or
core needle biopsy. However, according to literature, there
are no considerable diagnostic value differences between
these choices, but we presume that CNB is associated with
smaller percentage of uninformative samples and repeated
procedures respectively (Rao et al., 2009). Another disad-
vantage of the study was the inclusion of three cases where
percutaneous biopsy after NAC was proposed, but rejected
because of completely unaffected axillary imaging and tech-
nical difficulties to perform needle biopsy on very small
size lymph nodes.
Like other studies, we report significantly lower axillary
pCR rate in Luminal subtype breast cancers (Boughey et al.,
2014). Lobular breast cancers have extremely low rates of
pCR after NAC. As there were only three lobular cancer
cases in our cohort, the sample size was too small for analy-
sis (Loibl et al., 2014) (Johnson et al., 2016).
CONCLUSION
FNAC after NAC had a low 12% false positive rate and can
aid to predict residual axillary disease and assist in surgical
decision making regarding ALND. However, the false nega-
tive rate was unacceptable high and FNAC alone could not
be able to predict ypCR and omission of further axillary
surgery. In many cases, ACS is still the most optimal
method to restage the axilla after NAC.
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PERKUTÂNAS ADATAS BIOPSIJAS METOÞU NOZÎME PADUSES LIMFMEZGLU METASTÂÞU IZVÇRTÇÐANAI KRÛTS VÇÞA
PACIENTÇM PÇC NEOADJUVANTAS ÍÎMIJTERAPIJAS
Pçtîjuma mçríis ir izvçrtçt tievâs adatas aspirâcijas citoloìijas nozîmi pçc neoadjuvantas íîmijterapijas krûts vçþa pacientçm ar metastâzçm
paduses limfmezglos. Pçtîjumâ tika iekïauti 90 krûts vçþa IIA–IIIC stadijas gadîjumi, kuros konstatçtas metastâzes paduses limfmezglos un,
kas saòçma neoadjuvantu íîmijterapiju. Lielâkais, virspusçjâkais un visvairâk kaudâli novietotais paduses limfmezgls, kurâ citoloìiski tika
konstatçtas metastâzes, tika maríçts ar klipu. Pçc neoadjuvantas íîmijterapijas atkârtoti tika veikta ultrasonogrâfiska paduses limfmezglu
izvçrtçðana un tievâs adatas aspirâcijas citoloìija maríçtajam limfmezglam un/vai visvairâk suspektajam paduses limfmezglam. 58/90
gadîjumos bija pieejami perkutânâs adatas biopsijas dati, un ðî pacientu grupa tika pçtîta detalizçti. 37/58 gadîjumos tika veikta padusi
saudzçjoða operâcija, bet 21/58 gadîjumâ — paduses limfadenektomija. Tievâs adatas aspirâcijas dati pçc neoadjuvantas íîmijterapijas tika
salîdzinâti ar paduses operâcijas datiem. Tievâs adatas aspirâcijas viltus pozitîvâ vçrtîba pçc neoadjuvantas íîmijterapijas ir 12%, viltus
negatîvâ vçrtîba — 58%, jutîgums — 54%, specifiskums — 82%, precizitâte — 62%. Tievâs adatas aspirâcijas citoloìijas gadîjumâ viltus
pozitîvâ vçrtîba ir zema un testu ir lietderîgi izmantot, lai prognozçtu reziduâlas metastâzes paduses limfmezglos un jau pirms operâcijas
izðíirtos par operâcijas apjomu — paduses limfadenektomiju. Tomçr viltus negatîvâ vçrtîba ir pârlieku augsta, un testu nevar izmantot, lai
prognozçtu pilnu patoloìisku remisiju paduses limfmezglos, kas potenciâli ïautu izvairîties no radikâlas paduses operâcijas.
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